About Us
Who we are:
SDS Life Sciences is one of India’s leading manufacturers of radiopharmaceuticals, dedicated to empowering nuclear medicine centers and hospitals across the country. With a strong foundation in innovation and quality, we specialize in the production of Technetium-99m (Tc-99m) Generators and Iodine-131 (I-131) Solutions and Capsules, used extensively in the diagnosis and treatment of cancer and other critical diseases.
Driven by our commitment to excellence, we follow stringent cGMP standards and adhere to all regulatory norms. Our products are designed and manufactured in state-of-the-art facilities to ensure safety, reliability, and consistent performance in every batch.
SDS Life Sciences strives to make advanced radiopharmaceuticals more accessible and affordable. Our mission is to advance nuclear medicine through innovation, precision, and integrity, contributing to improved patient outcomes and better healthcare delivery worldwide.
Vision and Commitment
Our vision is to become Asia’s leading producer of radiopharmaceuticals, providing a complete range of products that advance nuclear medicine and improve patient care.
We are committed to innovation, reliability, and the highest quality standards, supporting healthcare professionals across India and beyond.
Our Facilities
SDS Life Sciences operates two state-of-the-art manufacturing facilities strategically located in North and South India, ensuring efficient production and nationwide distribution of high-quality radiopharmaceuticals.
Facility 1 – Manesar, Haryana (Near Delhi, North India)
Our Manesar facility is a WHO-GMP certified state of the art production unit which specializes in the production of Mo-99/Tc-99m Technetium Generators, Iodine-131 Capsules and Solutions, and Lutetium-177–labelled products. The generator manufacturing line was supplied by ITD, Germany (now part of Eckert & Ziegler), incorporating advanced European technology to ensure reliability, precision, and purity.
Facility 2 – Visakhapatnam, Andhra Pradesh (South India)
Our Visakhapatnam facility focuses on the production of Fludeoxyglucose (FDG) and other F-18–based radiopharmaceuticals, utilizing an 18 MeV, 300 µA medical cyclotron (KIUBE 300) from IBA, Belgium. This advanced infrastructure enables the supply of high-purity PET radiotracers for oncology, neurology, and cardiology applications.
Both facilities are fully compliant with AERB (Atomic Energy Regulatory Board) safety regulations and adhere to all Indian regulatory requirements. They are accredited with ISO 9001:2015 certifications, reflecting our commitment to maintaining global standards in quality, safety, and operational excellence.
Director’s Message
SDS Life Sciences began its journey in 2015 with the production of the Tc-99m generator — the workhorse of the nuclear medicine industry. This was the first Tc-99m generator manufacturing facility in the Indian private sector. Over time, we grew to become the largest Tc-99m generator producer in the country, successfully competing with global companies that were importing generators into India. This achievement strengthened our resolve to expand our nuclear medicine portfolio through world-class, Make-in-India radiopharmaceutical solutions.
In 2024, we further expanded our capabilities with two new state-of-the-art facilities:
- One dedicated to the production of Iodine solutions and capsules, and
- Another for the production of FDG and other F-18–based radiopharmaceuticals.
These additions have positioned SDS Life Sciences as the largest radiopharmaceutical producer in the Indian private sector. Today, we cater to more than 200 hospitals and nuclear medicine centres across the country.
We have consistently invested in the best technologies and equipment to ensure superior product quality and reliable supply. Our plants are equipped with machinery sourced from global leaders such as ITD Germany (now Eckhert and Zieglar) , IBA Belgium, and Von Gahlen Netherlands. We are accredited with WHO-GMP and ISO certifications, reaffirming our commitment to global quality standards.
Our vision is to become Asia’s leading producer of radiopharmaceuticals, offering a comprehensive range of products that advance nuclear medicine and improve patient care.
To realize this vision, we are also looking at backward integration into isotope production through irradiation in reactors and cyclotrons. Over the next five years, we aim to supply a comprehensive range of radiopharmaceuticals and associated products. We also plan to establish a dedicated research and radiopharmacy centre for the development of new, value-added products for the Indian and Asian markets. We are confident of establishing our footprint across all major countries in Asia.
I take this opportunity to express my sincere gratitude to our employees, whose hard work and dedication have brought the company to where it stands today. I would also like to thank all our customers and business partners for their unwavering support. I foresee a bright future for SDS Life Sciences as we continue to empower the nuclear medicine industry in India.
About the Directors
Mr. K. M. Sharan – Director
Mr. K. M. Sharan is the founder of SDS Life Sciences. He established the company with the vision of creating radiopharmaceutical manufacturing capabilities in the private sector at a time when such initiatives were rare in India.
A Civil Engineer by profession, Mr. Sharan has had a distinguished career in public service. He joined the Indian Railway Services (Government of India) in 1957 and served in several senior engineering and administrative roles. He retired as Chief Engineer, Indian Railways, in 1989.
His extensive experience in infrastructure development and project management continues to guide the company’s growth and long-term direction.
Mr. Ajit M. Sharan – Director
Mr. Ajit M. Sharan is an Electrical & Electronics Engineer from the prestigious Indian Institute of Technology, Delhi (IIT Delhi) and a former civil servant. He joined the Indian Administrative Service (IAS) in 1979 and held several key positions across both state and central government. He retired in 2017 as Secretary to the Government of India.
He currently serves on the Board of Dabur India Ltd., one of India’s leading FMCG companies and among the most trusted consumer brands in the country. His expertise in policy, governance, and corporate leadership brings immense value to SDS Life Sciences, contributing significantly to the company’s strategic and operational decisions.
Gallery
